Skip to main content

Table 2 Baseline and follow-up VAS, SPADI-pain, -disability and -total scales within and between the two groups

From: Effectiveness of lyophilized growth factors injection for subacromial impingement syndrome: a prospective randomized double-blind placebo-controlled study

  

Saline group

n = 30

mean ± SD

L-GF group

n = 30

mean ± SD

t2

p2

VAS

Baseline

7.67 ± 1.92

6.90 ± 1.83

1.586

0.118

Follow-up

5.87 ± 2.60

3.97 ± 2.57

2.851

0.006*

t1

3.949

7.478

  

p1

 < 0.001*

< 0.001*

  

% Change

1.80 ± 2.50

2.93 ± 2.15

− 1.884

0.065

SPADI-pain (%)

Baseline

69.37 ± 17.19

60.03 ± 16.75

2.130

0.037*

Follow-up

55.95 ± 27.02

39.20 ± 24.26

2.527

0.014*

t1

2.843

4.851

  

p1

0.008*

 < 0.001*

  

% Change

13.42 ± 25.85

20.83 ± 23.52

− 1.162

0.250

SPADI-Disability (%)

Baseline

56.40 ± 19.35

47.73 ± 19.96

1.708

0.093

Follow-up

48.50 ± 25.58

28.67 ± 20.52

3.312

0.002*

t1

1.819

4.565

  

p1

0.079

 < 0.001*

  

% Change

7.90 ± 23.77

19.05 ± 22.86

− 1.853

0.069

SPADI-total (%)

Baseline

61.28 ± 16.76

52.63 ± 16.65

2.006

0.050*

Follow-up

51.36 ± 24.92

32.87 ± 20.61

3.132

0.003*

t1

2.356

5.084

  

p1

0.025*

 < 0.001*

  

% Change

9.27 ± 23.76

19.88 ± 21.09

-1.829

0.073

  1. VAS visual analogue scale, SPADI shoulder pain and disability index, SD Standard deviation, t1: paired samples t test, t2: independent samples t test, p1: of paired samples t test, p2: of independent samples t test
  2. *Statistically significant at p ≤ 0.05